Halofuginone: Preliminary Phase Ib/IIa data

Preliminary data from 12 boys and young men with ambulatory or non-ambulatory DMD in the open-label, U.S. Phase Ib/IIa HALO-DMD-01/02 trial showed that once-daily doses of 0.3-1.2 mg HT-100 for up to ...